Aug 27 (Reuters) - ProMetic Life Sciences Inc PLI.TO :
* Prometic's pbi-4050's positive safety review triggers expansion of phase II
clinical trial in metabolic syndrome patients
* Says pbi-4050 has been confirmed to be safe and well tolerated in the first
12 metabolic syndrome
* Prometic is now proceeding with the enrollment of an additional 24 patients,
as planned in the study protocol design
* Study is also investigating the effects of the drug on pro-inflammatory,
pro-fibrotic and metabolic biomarkers in patients
* Says anticipates having partial read out on biomarkers on pbi-4050 available
before the end of this year
* Source text for Eikon ID:nMKWPqnGFa